Neukio Biotherapeutics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An innovator in next-generation cell therapies for oncology, focusing on enhanced safety and efficacy.
Oncology
Technology Platform
A next-generation cell engineering platform for developing enhanced CAR-T and CAR-NK therapies with improved safety and efficacy profiles.
Opportunities
The large and growing oncology market in China, combined with potential for 'off-the-shelf' products, presents a major commercial opportunity.
Risk Factors
Clinical risks include managing toxicity (e.g., CRS, neurotoxicity) and demonstrating durable efficacy, especially in solid tumors.
Competitive Landscape
Operates in a highly competitive Chinese cell therapy market with many players targeting similar hematological cancers, requiring clear differentiation in technology or clinical outcomes.